A Open-label, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of Epcoritamab and Rituximab for Patients with Untreated Follicular Lymphoma (FL)

Protocol No

DFCI-22-702

Phase

II

Summary

The purpose of this study is to determine how effective and safe the combination of rituximab and epcoritamab is in treating patients with FL and who have not received other treatments for their lymphoma

Description

The purpose of this study is to determine how effective and safe the combination of rituximab and epcoritamab is in treating patients with FL and who have not received other treatments for their lymphoma

Participating Institutions

Froedtert Hospital

Status

IRB INITIAL APPROVAL